Precision Pharma Services Merges Into Talecris Biotherapeutics

Talecris Biotherapeutics, Inc. (TBI) recently announced the merger of Precision Pharma Services, a wholly owned Talecris subsidiary, into TBI. Precision Pharma of Melville, New York was acquired by Talecris' parent company in 2005, and maintained its name and separate operations until this merger.

The 140 highly skilled employees located in Melville will remain at that location, and will officially become part of the global team of Talecris employees. Talecris will fully integrate the former Precision employees into the Talecris organization, while continuing to focus on quality, safety, compliance and overall product excellence, from the arm of the plasma donor to the arm of the patients.

"Since the acquisition, the people and facility in Melville have been critical to our manufacturing process by significantly increasing our fractionation capacity and contract services business," said Mary Kuhn, Senior Vice President of Operations for Talecris Biotherapeutics. "This merger combines the Melville facility's expertise with the Talecris Clayton facility's expertise to continue our commitment to the patient communities who rely on our products."

Precision Pharma is an experienced outsourcing partner providing quality manufacturing and testing services to the biotechnology and pharmaceutical industries. Among these services are aseptic filling and product manufacturing ranging from plasma fractionation to pharmaceutical compounding to separation, extraction, concentration and purification of complex molecules.

"The Precision Pharma culture is rooted in performance and continuous improvement--two qualities that define the Talecris business model," said Frank Sauers, Senior Director, Melville Operations. "By operating under one brand, we can truly realize the vision of global market leadership in product innovation, quality, and safety."

About Talecris Biotherapeutics: Inspiration. Dedication. Innovation.
Talecris Biotherapeutics is a global biotherapeutic and biotechnology company that discovers, develops and produces critical care treatments for people with life-threatening disorders in a variety of therapeutic areas including immunology, pulmonology, and hemostasis. Talecris is proudly building upon a 60-year legacy of innovation and a commitment to improving the lives of people who rely on its therapeutic products. With an emphasis on scientific inquiry and technological excellence, Talecris is expanding its current portfolio of products, programs, and services through its own world-class product development organization as well as through strategic initiatives that leverage its strengths with those of its partners.

Talecris, with revenues of approximately $1.2 billion in 2007, is headquartered in biotech hub Research Triangle Park, N.C., and employs more than 4,000 talented people worldwide.

To learn more about Talecris and how our employees are making a difference in the lives of patients and the healthcare community, visit www.talecris.com.

SOURCE: <%=company1%>